ChemoCentryx, Inc. (CCXI) said Monday that it has commenced an underwritten public offering of $60 million of its common stock.
In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold to cover over-allotments, if any.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.
All shares of the common stock to be sold in the offering will be offered by ChemoCentryx.
The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the company said.
For comments and feedback: editorial@rttnews.com